Alcami Announces CEO Transition
Alcami , a leading contract development and manufacturing organization (CDMO), has announced a leadership transition with Chairman of the Board Patrick Walsh stepping in as Interim CEO following Bill Humphries' resignation. Walsh, who previously served as CEO of Alcami on two occasions and has been Chairman for the past four years, will ensure operational continuity and maintain the company's client-focused approach.
During his two-year tenure, Humphries led Alcami through a period of facilities expansion and global supply chain realignment. Walsh currently holds several leadership positions, including Chairman of ANI Pharmaceuticals (NASDAQ: ANIP), Chairman of MedPharm, and Operating Partner at Ampersand Capital Partners.
Alcami, una delle principali organizzazioni di sviluppo e produzione a contratto (CDMO), ha annunciato un cambio di leadership con il Presidente del Consiglio Patrick Walsh che assumerà il ruolo di CEO ad interim dopo le dimissioni di Bill Humphries. Walsh, che in precedenza ha ricoperto il ruolo di CEO di Alcami in due occasioni ed è stato Presidente negli ultimi quattro anni, garantirà la continuità operativa e manterrà l'approccio orientato al cliente dell'azienda.
Durante il suo mandato di due anni, Humphries ha guidato Alcami attraverso un periodo di espansione delle strutture e riallineamento della catena di approvvigionamento globale. Walsh ricopre attualmente diverse posizioni di leadership, incluso il ruolo di Presidente di ANI Pharmaceuticals (NASDAQ: ANIP), Presidente di MedPharm e Partner operativo presso Ampersand Capital Partners.
Alcami, una de las principales organizaciones de desarrollo y fabricación por contrato (CDMO), ha anunciado una transición de liderazgo con el presidente de la junta, Patrick Walsh, asumiendo el cargo de CEO interino tras la renuncia de Bill Humphries. Walsh, quien anteriormente se desempeñó como CEO de Alcami en dos ocasiones y ha sido presidente durante los últimos cuatro años, asegurará la continuidad operativa y mantendrá el enfoque centrado en el cliente de la empresa.
Durante su mandato de dos años, Humphries lideró a Alcami a través de un período de expansión de instalaciones y reorganización de la cadena de suministro global. Actualmente, Walsh ocupa varios cargos de liderazgo, incluyendo el de presidente de ANI Pharmaceuticals (NASDAQ: ANIP), presidente de MedPharm y socio operativo en Ampersand Capital Partners.
알카미(Alcami)는 주요 계약 개발 및 제조 조직(CDMO)으로서, 빌 험프리(Bill Humphries)의 사임에 따라 이사회 의장 패트릭 월시(Patrick Walsh)가 임시 CEO로 임명되는 리더십 전환을 발표했습니다. 이전에 두 차례 알카미 CEO로 재직했던 월시는 지난 4년 동안 이사회 의장으로 재직하였으며, 운영의 연속성을 보장하고 회사의 고객 중심 접근 방식을 유지할 것입니다.
2년 간의 재임 기간 동안 험프리는 알카미를 시설 확장 및 글로벌 공급망 재조정 시기를 거치며 이끌었습니다. 현재 월시는 ANI Pharmaceuticals (NASDA: ANIP)의 의장, 메드팜(MedPharm)의 의장, 앰퍼샌드 캐피탈 파트너스(Ampersand Capital Partners)의 운영 파트너 등 여러 리더십 직책을 겸하고 있습니다.
Alcami, une organisation leader dans le développement et la fabrication sous contrat (CDMO), a annoncé une transition de leadership, avec le président du conseil Patrick Walsh prenant le poste de PDG par intérim suite à la démission de Bill Humphries. Walsh, qui a précédemment été PDG d'Alcami à deux reprises et a été président au cours des quatre dernières années, garantira la continuité opérationnelle et maintiendra l'approche axée sur le client de l'entreprise.
Au cours de son mandat de deux ans, Humphries a dirigé Alcami à travers une période d'expansion des installations et de réalignement de la chaîne d'approvisionnement mondiale. Walsh occupe actuellement plusieurs postes de direction, y compris président de ANI Pharmaceuticals (NASDAQ: ANIP), président de MedPharm et partenaire opérationnel chez Ampersand Capital Partners.
Alcami, eine führende Organisation für Vertragsentwicklung und -herstellung (CDMO), hat einen Leitungswechsel angekündigt, bei dem der Vorsitzende des Vorstands, Patrick Walsh, nach dem Rücktritt von Bill Humphries als Interims-CEO einspringt. Walsh, der zuvor zweimal als CEO von Alcami fungierte und in den letzten vier Jahren Vorsitzender war, wird die betriebliche Kontinuität sicherstellen und den kundenorientierten Ansatz des Unternehmens beibehalten.
Während seiner zweijährigen Amtszeit leitete Humphries Alcami durch eine Phase der Expansion der Einrichtungen und Neuausrichtung der globalen Lieferkette. Walsh bekleidet derzeit mehrere Führungspositionen, darunter den Vorsitz von ANI Pharmaceuticals (NASDAQ: ANIP), Vorsitz von MedPharm und Betriebsleiter bei Ampersand Capital Partners.
- None.
- None.
Long time industry leader, Chairman of the Board Patrick Walsh replaces CEO Bill Humphries
"On behalf of the Board, I'd like to express gratitude to Bill for his leadership over the last two years during a critical time of facilities expansion and a global supply chain realignment. He was a strong advocate for our clients and the organization benefited from his leadership. I am personally grateful for his contributions and wish him all the best in his new opportunity," commented Walsh.
Mr. Walsh served as CEO of Alcami on two previous occasions and has served as Chairman over the last four years. In addition to his duties at Alcami, he currently serves as Chairman of ANI Pharmaceuticals, Inc. (NASDAQ: ANIP), Chairman of MedPharm, and is an Operating Partner at Ampersand Capital Partners.
About Alcami
Alcami is a US-based contract development and manufacturing organization (CDMO) headquartered in NC with 45+ years of experience advancing pharmaceuticals and biologics from development to delivery. Alcami provides fully integrated lab services, drug product manufacturing, and cGMP pharma storage and support services including environmental monitoring, calibration, and validation. Alcami's private equity ownership includes GHO Capital, The Vistria Group, and Ampersand Capital Partners. For more information, please visit alcami.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/alcami-announces-ceo-transition-302349441.html
SOURCE Alcami Corporation
FAQ
Who is replacing Bill Humphries as CEO of Alcami in January 2025?
What major initiatives did Bill Humphries oversee during his tenure at Alcami?
What other leadership positions does Patrick Walsh currently hold?
How many times has Patrick Walsh previously served as Alcami's CEO?
